Innovation1 Biotech Inc (MYYZ) Return on Equity ROE from the second quarter 2024 to second quarter 2023 and annually, average high and low, overall ranking from Feb 29 2024 to Feb 28 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Innovation1 Biotech Inc   (MYYZ)

Innovation1 Biotech Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Innovation1 Biotech Inc in the second quarter 2024?
Due to the lack of equity, it was not possible to calculate Innovation1 Biotech Inc 's return on equity (ROE) in its second quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Feb 29 2024)
II. Quarter		 (Nov 30 2023)
I. Quarter		 (Aug 31 2023)
IV. Quarter		 (May 31 2023)
III. Quarter		 (Feb 28 2023)
II. Quarter
Y / Y Equity Change - - - -96.89 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -5 -13 -13 -46 -47
Return On Equity (TTM) - - -3806.7 % -2398.21 % -404.89 %
MYYZ's Total Ranking # # # # #
Equity (TTM) in Millions -3 -3 -3 1 1
Seq. Equity Change - - - -15.33 % -29.03 %
Seq. Net Income Change - - - - -

Back to MYYZ Management Effectiveness >> MYYZ's 5 Years Annual ROE >> Compare MYYZ ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





MYYZ Annual Return On Equity (Aug 31 2023)
2023		 (Aug 31 2022)
2022		 (Aug 31 2021)
2021		 (Aug 31 2020)
2020		 (Aug 31 2019)
2019
Total Equity in Millions -3 3 0 -3 0
Y / Y Equity Change - - - - -81.6 %
Net Income in Millions -13 -41 1 -3 0
Y / Y Net Income Change - - - - -
Return On Equity - -1433.01 % - - -525.53 %

Back to MYYZ Management Effectiveness >> MYYZ's 5 Years Annual ROE >> Compare MYYZ ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MYYZ's' Return on Equity at Yahoo Finance
MYYZ's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MYYZ's Competitors
Subscribers only: Roe for Innovation1 Biotech Inc 's Suppliers
Subscribers only: Return On Equity for MYYZ's Customers




Companies with similar Return On Equity at Feb 29 2024, within Healthcare Sector ROE
Biomx Inc  595.88 %
Cardiff Lexington Corporation  552.36 %
Ir med Inc   481.97 %
Merrimack Pharmaceuticals Inc  288.18 %
WEED, INC.  249.65 %
Ladrx Corporation  207.75 %
Glucotrack Inc   207.15 %
Halozyme Therapeutics Inc   192.68 %
Scynexis Inc   122.03 %
Viskase Holdings inc   118.99 %
Mimedx Group Inc   116.14 %
Roivant Sciences Ltd   107.85 %
Entera Bio Ltd   103.40 %
Tenet Healthcare Corp  98.05 %
Davita Inc   88.05 %
Dariohealth Corp   76.11 %
Arcutis Biotherapeutics Inc   69.56 %
Scienture Holdings Inc   66.82 %
Idexx Laboratories Inc  63.66 %
Waters Corporation  63.25 %
Enzo Biochem Inc  61.16 %
Lantheus Holdings Inc   61.14 %
Medpace Holdings Inc   59.74 %
Amgen Inc   58.59 %
Abbvie Inc   55.25 %
Nrc Health  54.83 %
Johnson and Johnson  53.73 %
Eli Lilly And Company  53.13 %
Siga Technologies Inc  51.97 %
Elite Pharmaceuticals Inc   49.73 %

Date modified: 2026-09-08T15:11:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.